ALK and non-small cell lung carcinoma: In the Impower150 study that was also regardless of PD-L1 expression, the combination of atezolizumab, bevacizumab, plus chemotherapy significantly improved PFS and OS among patients with metastatic non-squamous NSCLC, regardless of EGFR or ALK genetic mutations (27).